FDA updates its ADHD treatment guidance as school year begins

FDA has updated its "Treating and Dealing with ADHD" resource section to inform consumers about FDA-approved treatments to help reduce ADHD symptoms and improve functioning in children as young as age 6. Treatments include both stimulants and four non-stimulants: Strattera (atomoxetine), Intuniv (guanfacine), Kapvay (clonidine), and Qelbree (viloxazine). Studies show that children with untreated ADHD have more ED visits and are more likely to have self-inflicted injuries than those treated for the disorder.